Michele Buzhardt
About
Detail
Sr. VP of Sales
United States
Résumé
Jobs
verified_user
0% verified
Sr. VP of SalesNeoGenomics LaboratoriesJan 2022 - Current (4 years 8 months)- VP of SalesNeoGenomics LaboratoriesJan 2019 - Jan 2022 (3 years 1 month)
- Regional Business Unit Leader- NortheastGenoptix IncMar 2017 - Dec 2018 (1 year 10 months)Regional Business Unit Leader over 9 territories spanning: North Carolina, Virginia, West Virginia, Maryland, Delaware, New Jersey, New York, Pennsylvania, Ohio, Massachusetts, Connecticut, Rhode Island, New Hampshire, Vermont and Maine.
- District Sales ManagerGenoptix IncJul 2016 - Mar 2017 (9 months)
- District Manager-East Coast (Companion Diagnostics)Genoptix IncMay 2013 - Jun 2016 (3 years 2 months)
- Diagnostic Sales ConsultantGenoptix IncJan 2012 - May 2013 (1 year 5 months)• Achieved President’s Club (ranked #7/80) • 117% to Goal in 2012 • $2.9 million in sales in 2012 (53% year over year growth) • Achieved Century Club • Ranked 3rd for Novartis Performance Frontier Award • Added 23 new customers and 8 new hospital accounts • Awarded top place for two role plays at National Sales Meeting • Only sales representative in region to close business on all new products • Knowledgeable of client billing in hospital and private practice setting
- Senior Oncology Account ManagerGenoptix IncApr 2011 - Dec 2011 (9 months)• 101% to Goal • $1.9 million in sales in 2011 • Ranked in top 12 for Q2 and Q4 • Achieved Century Club • Recognized as MVP of South Atlantic District for 2011
- Oncology Account ManagerGenoptix IncOct 2010 - Apr 2011 (7 months)
- Oncology Research ScientistMayo ClinicJan 2007 - Oct 2010 (3 years 10 months)Investigated signaling pathways and evaluated potential chemo-preventative and chemotherapeutic agents across several cancer types: breast cancer, pancreatic cancer, lung cancer, and colon cancer. Conducted research with experience in clinical investigation trials and translational research for the development of innovative therapies.
- DResearch Scientist at Greenville Oncology Research InstituteDepartment of Oncology Greenville Hospital SystemJan 2002 - Dec 2006 (5 years)Advancing novel targeted therapies in breast cancer.
- Immunology ScientistClemson UniversityJan 2000 - Dec 2001 (2 years)Conducted research in the area of cellular immunology and immuno-biology.
- EPharmaceutical ResearchEquiTox Pharmaceutical Research DevelopmentJan 1998 - Jan 2000 (2 years 1 month)Research driven pharmaceutical company dedicated to finding a solution to Equine Fescue Toxicosis.
Education
verified_user
0% verified
- PhD, Molecular MedicineClemson UniversityJan 2002 - Jan 2006 (4 years 1 month)Dissertation Topic: Investigating the role of prolactin and its antagonist in HER2/neu tumorigenesis and the potential benefit of using a prolactin receptor antagonist and Herceptin in HER2 positive breast cancer.
- Master of Science, Animal Physiology / ImmunologyClemson UniversityJan 2000 - Jan 2002 (2 years 1 month)Thesis Topic: Investigating the influences of laminin and monoclonal antibody A4 on proliferation of peripheral blood lymphocytes.
- Bachelor of Science, Mathematical Sciences and BiologyClemson UniversityJan 1996 - Jan 1999 (3 years 1 month)
Publications
verified_user
0% verified
- CProtein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis.Cancer Research Mar
- CProtein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis.Cancer Research Mar
- NProtein kinase D1 drives pancreatic acinar cell reprogramming and progression to intraepithelial neoplasia.Nat Commun Febthe transdifferentiation of pancreatic acinar cells to a ductal phenotype (acinar-to-ductal metaplasia, adm) occurs after injury or inflammation of the pancreas and is a reversible process. however, in the presence of activating kras mutations or persistent epidermal growth factor receptor (egf-r) signalling, cells that underwent adm can progress to pancreatic intraepithelial neoplasia (panin) and eventually pancreatic cancer. in transgenic animal models, adm and panins are initiated by high-affinity ligands for egf-r or activating kras mutations, but the underlying signalling mechanisms are not well understood. here, using a conditional knockout approach, we show that protein kinase d1 (pkd1) is sufficient to drive the reprogramming proces
- PProtein kinase C zeta regulates human pancreatic cancer cell transformed growth and invasion through a STAT3-dependent mPLoS One Aug
- BAdditive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast caBreast Cancer Res Treat Sep Oct
- PProtein kinase C iota regulates pancreatic acinar-to-ductal metaplasia.PLoS One Feb